Bevacizumab in breast cancer: fundamental questions remain.

Miles, David W

Miles, David W.

Affiliation

Miles DW; Mount Vernon Cancer Centre, Northwood, Middlesex HA6 2RN, UK. david.miles@doctors.org.uk

Lancet Oncol ; 14(2): 99-101, 2013 Feb.

Article in En | MEDLINE | ID: mdl-23369679

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Breast Neoplasms/pathology; Deoxycytidine/analogs & derivatives; Fluorouracil/analogs & derivatives; Paclitaxel/therapeutic use; Bevacizumab; Capecitabine; Deoxycytidine/therapeutic use; Female; Fluorouracil/therapeutic use; Humans

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Paclitaxel / Deoxycytidine / Antibodies, Monoclonal, Humanized / Fluorouracil Limits: Female / Humans Language: En Year: 2013 Type: Article

Fulltext

XML

PubMed Links

Search on Google